The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Genetic COPD Market Research Report 2025
Synopsis
For some people, their COPD is actually related to a rare genetic condition called alpha1-antitrypsin deficiency, or alpha-1 for short. This condition is sometimes referred to as "genetic COPD," and is caused by a deficiency in a specific protein called alpha1-antitrypsin.
The global Genetic COPD market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Genetic COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic COPD.
Report Scope
The Genetic COPD market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Genetic COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genetic COPD companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Genetic COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
For some people, their COPD is actually related to a rare genetic condition called alpha1-antitrypsin deficiency, or alpha-1 for short. This condition is sometimes referred to as "genetic COPD," and is caused by a deficiency in a specific protein called alpha1-antitrypsin.
The global Genetic COPD market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Genetic COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Genetic COPD.
Report Scope
The Genetic COPD market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Genetic COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Genetic COPD companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Vertex Pharmaceuticals
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Kedrion Group
ProMetic Life Sciences
Segment by Type
Augmentation Therapy
Cystic Fibrosis(CF)
Non-CF Bronchiectasis(NCFB)
Other
Segment by Application
Hospitals
Specialty Clinics
Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Genetic COPD companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Genetic COPD Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Augmentation Therapy
1.2.3 Cystic Fibrosis(CF)
1.2.4 Non-CF Bronchiectasis(NCFB)
1.2.5 Other
1.3 Market by Application
1.3.1 Global Genetic COPD Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Genetic COPD Market Perspective (2019-2030)
2.2 Genetic COPD Growth Trends by Region
2.2.1 Global Genetic COPD Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Genetic COPD Historic Market Size by Region (2019-2024)
2.2.3 Genetic COPD Forecasted Market Size by Region (2025-2030)
2.3 Genetic COPD Market Dynamics
2.3.1 Genetic COPD Industry Trends
2.3.2 Genetic COPD Market Drivers
2.3.3 Genetic COPD Market Challenges
2.3.4 Genetic COPD Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Genetic COPD Players by Revenue
3.1.1 Global Top Genetic COPD Players by Revenue (2019-2024)
3.1.2 Global Genetic COPD Revenue Market Share by Players (2019-2024)
3.2 Global Genetic COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Genetic COPD Revenue
3.4 Global Genetic COPD Market Concentration Ratio
3.4.1 Global Genetic COPD Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Genetic COPD Revenue in 2023
3.5 Genetic COPD Key Players Head office and Area Served
3.6 Key Players Genetic COPD Product Solution and Service
3.7 Date of Enter into Genetic COPD Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Genetic COPD Breakdown Data by Type
4.1 Global Genetic COPD Historic Market Size by Type (2019-2024)
4.2 Global Genetic COPD Forecasted Market Size by Type (2025-2030)
5 Genetic COPD Breakdown Data by Application
5.1 Global Genetic COPD Historic Market Size by Application (2019-2024)
5.2 Global Genetic COPD Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Genetic COPD Market Size (2019-2030)
6.2 North America Genetic COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Genetic COPD Market Size by Country (2019-2024)
6.4 North America Genetic COPD Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Genetic COPD Market Size (2019-2030)
7.2 Europe Genetic COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Genetic COPD Market Size by Country (2019-2024)
7.4 Europe Genetic COPD Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Genetic COPD Market Size (2019-2030)
8.2 Asia-Pacific Genetic COPD Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Genetic COPD Market Size by Region (2019-2024)
8.4 Asia-Pacific Genetic COPD Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Genetic COPD Market Size (2019-2030)
9.2 Latin America Genetic COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Genetic COPD Market Size by Country (2019-2024)
9.4 Latin America Genetic COPD Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Genetic COPD Market Size (2019-2030)
10.2 Middle East & Africa Genetic COPD Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Genetic COPD Market Size by Country (2019-2024)
10.4 Middle East & Africa Genetic COPD Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Genetic COPD Introduction
11.1.4 Pfizer Revenue in Genetic COPD Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Baxter
11.2.1 Baxter Company Detail
11.2.2 Baxter Business Overview
11.2.3 Baxter Genetic COPD Introduction
11.2.4 Baxter Revenue in Genetic COPD Business (2019-2024)
11.2.5 Baxter Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Genetic COPD Introduction
11.3.4 AstraZeneca Revenue in Genetic COPD Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Grifols
11.4.1 Grifols Company Detail
11.4.2 Grifols Business Overview
11.4.3 Grifols Genetic COPD Introduction
11.4.4 Grifols Revenue in Genetic COPD Business (2019-2024)
11.4.5 Grifols Recent Development
11.5 Teva Pharmaceutical Industries
11.5.1 Teva Pharmaceutical Industries Company Detail
11.5.2 Teva Pharmaceutical Industries Business Overview
11.5.3 Teva Pharmaceutical Industries Genetic COPD Introduction
11.5.4 Teva Pharmaceutical Industries Revenue in Genetic COPD Business (2019-2024)
11.5.5 Teva Pharmaceutical Industries Recent Development
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Detail
11.6.2 Boehringer Ingelheim Business Overview
11.6.3 Boehringer Ingelheim Genetic COPD Introduction
11.6.4 Boehringer Ingelheim Revenue in Genetic COPD Business (2019-2024)
11.6.5 Boehringer Ingelheim Recent Development
11.7 Kamada Ltd
11.7.1 Kamada Ltd Company Detail
11.7.2 Kamada Ltd Business Overview
11.7.3 Kamada Ltd Genetic COPD Introduction
11.7.4 Kamada Ltd Revenue in Genetic COPD Business (2019-2024)
11.7.5 Kamada Ltd Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Genetic COPD Introduction
11.8.4 GlaxoSmithKline Revenue in Genetic COPD Business (2019-2024)
11.8.5 GlaxoSmithKline Recent Development
11.9 CSL Behring
11.9.1 CSL Behring Company Detail
11.9.2 CSL Behring Business Overview
11.9.3 CSL Behring Genetic COPD Introduction
11.9.4 CSL Behring Revenue in Genetic COPD Business (2019-2024)
11.9.5 CSL Behring Recent Development
11.10 Takeda
11.10.1 Takeda Company Detail
11.10.2 Takeda Business Overview
11.10.3 Takeda Genetic COPD Introduction
11.10.4 Takeda Revenue in Genetic COPD Business (2019-2024)
11.10.5 Takeda Recent Development
11.11 LFB Biomedicaments
11.11.1 LFB Biomedicaments Company Detail
11.11.2 LFB Biomedicaments Business Overview
11.11.3 LFB Biomedicaments Genetic COPD Introduction
11.11.4 LFB Biomedicaments Revenue in Genetic COPD Business (2019-2024)
11.11.5 LFB Biomedicaments Recent Development
11.12 Abeona Therapeutics
11.12.1 Abeona Therapeutics Company Detail
11.12.2 Abeona Therapeutics Business Overview
11.12.3 Abeona Therapeutics Genetic COPD Introduction
11.12.4 Abeona Therapeutics Revenue in Genetic COPD Business (2019-2024)
11.12.5 Abeona Therapeutics Recent Development
11.13 Biogen
11.13.1 Biogen Company Detail
11.13.2 Biogen Business Overview
11.13.3 Biogen Genetic COPD Introduction
11.13.4 Biogen Revenue in Genetic COPD Business (2019-2024)
11.13.5 Biogen Recent Development
11.14 Vertex Pharmaceuticals
11.14.1 Vertex Pharmaceuticals Company Detail
11.14.2 Vertex Pharmaceuticals Business Overview
11.14.3 Vertex Pharmaceuticals Genetic COPD Introduction
11.14.4 Vertex Pharmaceuticals Revenue in Genetic COPD Business (2019-2024)
11.14.5 Vertex Pharmaceuticals Recent Development
11.15 Baxalta
11.15.1 Baxalta Company Detail
11.15.2 Baxalta Business Overview
11.15.3 Baxalta Genetic COPD Introduction
11.15.4 Baxalta Revenue in Genetic COPD Business (2019-2024)
11.15.5 Baxalta Recent Development
11.16 Arrowhead Research Corporation
11.16.1 Arrowhead Research Corporation Company Detail
11.16.2 Arrowhead Research Corporation Business Overview
11.16.3 Arrowhead Research Corporation Genetic COPD Introduction
11.16.4 Arrowhead Research Corporation Revenue in Genetic COPD Business (2019-2024)
11.16.5 Arrowhead Research Corporation Recent Development
11.17 ProBioGen
11.17.1 ProBioGen Company Detail
11.17.2 ProBioGen Business Overview
11.17.3 ProBioGen Genetic COPD Introduction
11.17.4 ProBioGen Revenue in Genetic COPD Business (2019-2024)
11.17.5 ProBioGen Recent Development
11.18 Chiesi Pharmaceuticals
11.18.1 Chiesi Pharmaceuticals Company Detail
11.18.2 Chiesi Pharmaceuticals Business Overview
11.18.3 Chiesi Pharmaceuticals Genetic COPD Introduction
11.18.4 Chiesi Pharmaceuticals Revenue in Genetic COPD Business (2019-2024)
11.18.5 Chiesi Pharmaceuticals Recent Development
11.19 Kedrion Group
11.19.1 Kedrion Group Company Detail
11.19.2 Kedrion Group Business Overview
11.19.3 Kedrion Group Genetic COPD Introduction
11.19.4 Kedrion Group Revenue in Genetic COPD Business (2019-2024)
11.19.5 Kedrion Group Recent Development
11.20 ProMetic Life Sciences
11.20.1 ProMetic Life Sciences Company Detail
11.20.2 ProMetic Life Sciences Business Overview
11.20.3 ProMetic Life Sciences Genetic COPD Introduction
11.20.4 ProMetic Life Sciences Revenue in Genetic COPD Business (2019-2024)
11.20.5 ProMetic Life Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Genetic COPD Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Augmentation Therapy
Table 3. Key Players of Cystic Fibrosis(CF)
Table 4. Key Players of Non-CF Bronchiectasis(NCFB)
Table 5. Key Players of Other
Table 6. Global Genetic COPD Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Genetic COPD Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Genetic COPD Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Genetic COPD Market Share by Region (2019-2024)
Table 10. Global Genetic COPD Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Genetic COPD Market Share by Region (2025-2030)
Table 12. Genetic COPD Market Trends
Table 13. Genetic COPD Market Drivers
Table 14. Genetic COPD Market Challenges
Table 15. Genetic COPD Market Restraints
Table 16. Global Genetic COPD Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Genetic COPD Market Share by Players (2019-2024)
Table 18. Global Top Genetic COPD Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic COPD as of 2023)
Table 19. Ranking of Global Top Genetic COPD Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Genetic COPD Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Genetic COPD Product Solution and Service
Table 23. Date of Enter into Genetic COPD Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Genetic COPD Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Genetic COPD Revenue Market Share by Type (2019-2024)
Table 27. Global Genetic COPD Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Genetic COPD Revenue Market Share by Type (2025-2030)
Table 29. Global Genetic COPD Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Genetic COPD Revenue Market Share by Application (2019-2024)
Table 31. Global Genetic COPD Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Genetic COPD Revenue Market Share by Application (2025-2030)
Table 33. North America Genetic COPD Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Genetic COPD Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Genetic COPD Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Genetic COPD Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Genetic COPD Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Genetic COPD Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Genetic COPD Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Genetic COPD Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Genetic COPD Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Genetic COPD Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Genetic COPD Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Genetic COPD Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Genetic COPD Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Genetic COPD Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Genetic COPD Market Size by Country (2025-2030) & (US$ Million)
Table 48. Pfizer Company Detail
Table 49. Pfizer Business Overview
Table 50. Pfizer Genetic COPD Product
Table 51. Pfizer Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 52. Pfizer Recent Development
Table 53. Baxter Company Detail
Table 54. Baxter Business Overview
Table 55. Baxter Genetic COPD Product
Table 56. Baxter Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 57. Baxter Recent Development
Table 58. AstraZeneca Company Detail
Table 59. AstraZeneca Business Overview
Table 60. AstraZeneca Genetic COPD Product
Table 61. AstraZeneca Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 62. AstraZeneca Recent Development
Table 63. Grifols Company Detail
Table 64. Grifols Business Overview
Table 65. Grifols Genetic COPD Product
Table 66. Grifols Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 67. Grifols Recent Development
Table 68. Teva Pharmaceutical Industries Company Detail
Table 69. Teva Pharmaceutical Industries Business Overview
Table 70. Teva Pharmaceutical Industries Genetic COPD Product
Table 71. Teva Pharmaceutical Industries Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 72. Teva Pharmaceutical Industries Recent Development
Table 73. Boehringer Ingelheim Company Detail
Table 74. Boehringer Ingelheim Business Overview
Table 75. Boehringer Ingelheim Genetic COPD Product
Table 76. Boehringer Ingelheim Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 77. Boehringer Ingelheim Recent Development
Table 78. Kamada Ltd Company Detail
Table 79. Kamada Ltd Business Overview
Table 80. Kamada Ltd Genetic COPD Product
Table 81. Kamada Ltd Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 82. Kamada Ltd Recent Development
Table 83. GlaxoSmithKline Company Detail
Table 84. GlaxoSmithKline Business Overview
Table 85. GlaxoSmithKline Genetic COPD Product
Table 86. GlaxoSmithKline Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 87. GlaxoSmithKline Recent Development
Table 88. CSL Behring Company Detail
Table 89. CSL Behring Business Overview
Table 90. CSL Behring Genetic COPD Product
Table 91. CSL Behring Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 92. CSL Behring Recent Development
Table 93. Takeda Company Detail
Table 94. Takeda Business Overview
Table 95. Takeda Genetic COPD Product
Table 96. Takeda Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 97. Takeda Recent Development
Table 98. LFB Biomedicaments Company Detail
Table 99. LFB Biomedicaments Business Overview
Table 100. LFB Biomedicaments Genetic COPD Product
Table 101. LFB Biomedicaments Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 102. LFB Biomedicaments Recent Development
Table 103. Abeona Therapeutics Company Detail
Table 104. Abeona Therapeutics Business Overview
Table 105. Abeona Therapeutics Genetic COPD Product
Table 106. Abeona Therapeutics Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 107. Abeona Therapeutics Recent Development
Table 108. Biogen Company Detail
Table 109. Biogen Business Overview
Table 110. Biogen Genetic COPD Product
Table 111. Biogen Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 112. Biogen Recent Development
Table 113. Vertex Pharmaceuticals Company Detail
Table 114. Vertex Pharmaceuticals Business Overview
Table 115. Vertex Pharmaceuticals Genetic COPD Product
Table 116. Vertex Pharmaceuticals Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 117. Vertex Pharmaceuticals Recent Development
Table 118. Baxalta Company Detail
Table 119. Baxalta Business Overview
Table 120. Baxalta Genetic COPD Product
Table 121. Baxalta Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 122. Baxalta Recent Development
Table 123. Arrowhead Research Corporation Company Detail
Table 124. Arrowhead Research Corporation Business Overview
Table 125. Arrowhead Research Corporation Genetic COPD Product
Table 126. Arrowhead Research Corporation Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 127. Arrowhead Research Corporation Recent Development
Table 128. ProBioGen Company Detail
Table 129. ProBioGen Business Overview
Table 130. ProBioGen Genetic COPD Product
Table 131. ProBioGen Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 132. ProBioGen Recent Development
Table 133. Chiesi Pharmaceuticals Company Detail
Table 134. Chiesi Pharmaceuticals Business Overview
Table 135. Chiesi Pharmaceuticals Genetic COPD Product
Table 136. Chiesi Pharmaceuticals Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 137. Chiesi Pharmaceuticals Recent Development
Table 138. Kedrion Group Company Detail
Table 139. Kedrion Group Business Overview
Table 140. Kedrion Group Genetic COPD Product
Table 141. Kedrion Group Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 142. Kedrion Group Recent Development
Table 143. ProMetic Life Sciences Company Detail
Table 144. ProMetic Life Sciences Business Overview
Table 145. ProMetic Life Sciences Genetic COPD Product
Table 146. ProMetic Life Sciences Revenue in Genetic COPD Business (2019-2024) & (US$ Million)
Table 147. ProMetic Life Sciences Recent Development
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Genetic COPD Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Genetic COPD Market Share by Type: 2023 VS 2030
Figure 3. Augmentation Therapy Features
Figure 4. Cystic Fibrosis(CF) Features
Figure 5. Non-CF Bronchiectasis(NCFB) Features
Figure 6. Other Features
Figure 7. Global Genetic COPD Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Genetic COPD Market Share by Application: 2023 VS 2030
Figure 9. Hospitals Case Studies
Figure 10. Specialty Clinics Case Studies
Figure 11. Pharmacies Case Studies
Figure 12. Others Case Studies
Figure 13. Genetic COPD Report Years Considered
Figure 14. Global Genetic COPD Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Genetic COPD Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Genetic COPD Market Share by Region: 2023 VS 2030
Figure 17. Global Genetic COPD Market Share by Players in 2023
Figure 18. Global Top Genetic COPD Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genetic COPD as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Genetic COPD Revenue in 2023
Figure 20. North America Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Genetic COPD Market Share by Country (2019-2030)
Figure 22. United States Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Genetic COPD Market Share by Country (2019-2030)
Figure 26. Germany Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Genetic COPD Market Share by Region (2019-2030)
Figure 34. China Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Genetic COPD Market Share by Country (2019-2030)
Figure 42. Mexico Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Genetic COPD Market Share by Country (2019-2030)
Figure 46. Turkey Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Genetic COPD Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Pfizer Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 49. Baxter Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 50. AstraZeneca Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 51. Grifols Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 52. Teva Pharmaceutical Industries Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 53. Boehringer Ingelheim Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 54. Kamada Ltd Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 56. CSL Behring Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 57. Takeda Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 58. LFB Biomedicaments Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 59. Abeona Therapeutics Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 60. Biogen Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 61. Vertex Pharmaceuticals Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 62. Baxalta Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 63. Arrowhead Research Corporation Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 64. ProBioGen Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 65. Chiesi Pharmaceuticals Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 66. Kedrion Group Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 67. ProMetic Life Sciences Revenue Growth Rate in Genetic COPD Business (2019-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
